J9298 HCPCS code: Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
J9298 is the HCPCS Level II code for injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg. In 2024 Medicare paid an average of $145.80 per service for J9298 across 687,733 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 160 per day on outpatient hospital claims. Medicare volume rose 789% from 2022 to 2024 (77,378 to 687,733 services). In 2024, about 1,009 clinicians billed Medicare for J9298 for 875 beneficiaries; Florida, California, Texas accounted for 41% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2022-10-01 |
| Last action effective | 2022-10-01 |
Who bills J9298 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,009 |
| Medicare beneficiaries | 875 |
| States with claims | 24 |
| Share of services in top 3 states (Florida, California, Texas) | 41% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9298, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 77,378 | 220 | $174.39 | $138.96 |
| 2023 | 519,744 | 713 | $177.78 | $141.64 |
| 2024 | 687,733 | 875 | $183.00 | $145.80 |
States with the most J9298 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 108,040 | $145.84 |
| California | 88,951 | $145.74 |
| Texas | 61,760 | $147.56 |
| Maryland | 45,670 | $134.63 |
| Tennessee | 31,681 | $147.97 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 160 | Prescribing Information |
| practitioner claims | 160 | Prescribing Information |
What changed for J9298
- 2022-10-01: J9298 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9298?
J9298 is the HCPCS Level II code for injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg. Short descriptor: "Inj nivol relatlimab 3mg/1mg".
How much does Medicare pay for J9298?
In 2024, the average Medicare payment was $145.80 per service (average allowed $183.00).
Does Medicare cover J9298?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9298 can be billed per day?
160 on outpatient hospital claims; 160 on practitioner claims (NCCI medically unlikely edits).
Related J92 codes
- J9200 — Injection, floxuridine, 500 mg
- J9201 — Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
- J9202 — Goserelin acetate implant, per 3.6 mg
- J9203 — Injection, gemtuzumab ozogamicin, 0.1 mg
- J9204 — Injection, mogamulizumab-kpkc, 1 mg
- J9205 — Injection, irinotecan liposome, 1 mg
- J9206 — Injection, irinotecan, 20 mg
- J9207 — Injection, ixabepilone, 1 mg
- J9208 — Injection, ifosfamide, 1 gram
- J9209 — Injection, mesna, 200 mg
- J9210 — Injection, emapalumab-lzsg, 1 mg
- J9211 — Injection, idarubicin hydrochloride, 5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9298
- Watch J9298 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9298
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.